 |
Home | Contact Us | Site Map |
 |
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
 |
||
| Ganaxolone |
 |
| About Ganaxolone |
|
| Ganaxolone for Partial Complex Seizures | |
| References & Scientific Support |
|
|
|||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
|
|
Marinus is dedicated to bringing therapies to market to treat a number of severe central nervous system (CNS) disorders. The Company has ongoing and planned clinical trials in CNS indications. In addition to ganaxolone trials in adult partial seizures, the unique mechanism of action of the compound suggests potential for other CNS indications including posttraumatic stress disorder, catamenial seizures and postpartum depression. |
|||||||||||||||||||||||||||||||
| © Marinus Pharmaceuticals | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||